Wuxi Biologics
TOPIC
 / company

Wuxi Biologics

Wuxi Biologics
Wuxi Biologics
Wuxi Biologics is a pharmaceutical research and services company based in Wuxi, Jiangsu province. It counts 16 of the world's top 20 drug makers as customers and 28 of China's 50 largest medicine producers. The company supplied ingredients for AstraZeneca's Covid-19 vaccine. It is one of six businesses founded by its chairman Ge Li, along with Wuxi Apptec.
Chairman / President
Li Ge
CEO / Managing Director
Chen Zhisheng
CFO / Finance Director
Tu Ming
Industry
Biopharmaceutical
Website
wuxibiologics.com.cn
Headquarters address
No. 108 Mashan Meiliang Road, Binhu Distroct, Wuxi City, Jiangsu Province, China
Stock Code
SEHK:2269
Year founded
2010
last updated:
30 September, 2024
LATEST China Science NEWS

Cambodia’s China-backed canal on Mekong seen to put ‘fragile ecosystems’ at risk

videocam
Colourful smoke bombs mark the groundbreaking ceremony for the Funan Techo canal in Cambodia’s Kandal province, in August last year. Photo: AFP

Chinese scientists simulate ‘hunting’ Starlink satellites in orbit

15
A SpaceX rocket takes Starlink satellites into orbit. Photo: AP

Chinese scientists hope advanced laser will open gateway to new discoveries

9
The Advanced Attosecond Laser Infrastructure (AALI) will operate from two sites, in Dongguan in Guangdong and Xian in Shaanxi, and will generate light pulses lasting billionths of a billionth of a second. Photo: Xinhua

Shanghai and Beijing unveil plans to boost brain computer interface industry

videocam
6
The technology can be used to help treat paralysis and stroke vicims. Photo: Xinhua

China’s new technology achieves ‘unprecedented’ rare earth production speed

videocam
21
Conventional rare earth mining can have damaging environmental impacts, but a new method developed in China could be good news for the sector. Photo: Reuters/Stringer
MORE China Science NEWS
WuXi Biologics company logo. Photo: Shutterstock
Biomedicine: Companies

China’s WuXi Biologics to sell Irish vaccine facility to Merck as US curbs loom

US passed Biosecure Act which would ban federal contracts with targeted firms and their business partners. Legislation explicitly names WuXi.

Biomedicine: Companies

WuXi AppTec, WuXi Biologics surge on slimmer chances of Biosecure Act’s passage

Biomedicine: Policy

Shanghai to back local biopharma firms’ overseas push, regulatory compliance

videocam
Wuxi AppTec

WuXi AppTec, WuXi Biologics rise in Hong Kong as some operations go up for sale

The gains were made on the back of a report that said the two firms plan to sell certain overseas operations amid heightened US scrutiny.

The reported divestment plans of WuXi AppTec and WuXi Biologics show their efforts to head off the potential impact of the US Biosecure Act. Photo: Shutterstock
US-China relations

Senior US official lauds China cooperation on tech-transfer controls

‘End-use checks’ have improved since the pandemic, but pending congressional legislation is keeping mainland firms in limbo.

videocam
6
US-China relations

‘China week’ at US House puts biotech firms, Hong Kong offices in cross hairs

Most of the scheduled 28 items have bipartisan support and follow efforts to tackle national and economic security threats posed by Beijing.

videocam
19
Advertisement
Advertisement
Advertisement
Hong Kong stock market

Hong Kong stocks surrender rally as WuXi Bio slumps 21% while Tencent, Li Auto gain

Stocks declined, capping another week of losses, after WuXi Biologics suffered another major plunge. Market surrendered an earlier rally fuelled by favourable Beijing policy and robust EV deliveries in January.

13
People walking outside a building with running stock tickers in Tsim Sha Tsui, Hong Kong on November 21, 2023. Photo: Li Jiaxing
Hong Kong stock market

Hong Kong stocks rebound as WuXi Bio, Sands get support to stem market rout

Stocks rebound from a 13-month low, snapping a three-day slump. Some companies are quickly pushing for buy-backs to help stem losses and shore up market confidence.

IPO

Hong Kong IPO: WuXi Biologics unit eyes up to US$520 million in biotech push

WuXi XDC, a 60 per cent-owned unit of WuXi Biologics, could raise as much as US$520 million, including excess share allotment, based on the top end of its IPO price range.

videocam
IPO

China’s Wuxi Biologics to spin off international unit in Hong Kong IPO

Capital raised from the IPO of Wuxi XDC will go towards building new manufacturing facilities in Singapore, expanding production capacity in China, strategic investments and acquisitions, according to an exchange filing.

videocam
Wuxi Biologics holds a 60 per cent controlling stake in Wuxi XDC, which will remain its subsidiary after the spin-off. Photo: Wuxi Biologics
Hong Kong stock market

Most Hong Kong stocks rise as Beijing raises stimulus policy hopes

Most stocks on the Hang Seng Index rose on the prospect that Beijing will double down on policy measures to boost economic growth.

The Exchange Square Complex, which houses the Hong Kong Stock Exchange, pictured on July 13, 2022. Photo: Bloomberg
Hong Kong stock market

WuXi Biologics suspends trading after US list sparks record 32 per cent slump

WuXi Biologics sank by as much as 32 per cent, its steepest on record, before trading was suspended for an announcement. Some US$14.7 billion of market value in two related companies was erased in the sell-off.

videocam
Hong Kong stock market

Hang Seng slips as WuXi Biologics sink by record after US red-flag list

Stocks slipped for a second day after the US added 33 Chinese companies including WuXi Biologics under its ‘unverified’ list with export restrictions. Alibaba fell again amid speculation insiders are preparing to sell.

videocam
A-shares

Hong Kong stocks decline as Wuxi Biologics, Alibaba pace tech losses

Hong Kong stocks declined amid concerns a surge this week to a three-month high may be too excessive amid debates about the strength of global economic recovery and the outlook for Fed tapering.

videocam
A woman walks past a bank's electronic board showing the Hang Seng Index index on June 1. Photo: AP
Medicine

Investors swoop in on WuXi Biologics shares as owner trims stake

The sell-down programme by controlling shareholder Biologics Holdings has raised HK$54.9 billion (US$7.1 billion) in funds over 10 disposals since 2017.

WuXi Biologics, China site. Photo: Handout
Hang Seng Index

China’s telecom giants surge on NYSE reversal, WuXi slides as insider sells

Hong Kong and China stocks gained as Chinese telecom giants surged after the New York Stock Exchange scraps its delisting plan. WuXi Biologics slumped as an insider trimmed his stake for a second time in four months.

Hong Kong stock market

Hong Kong stocks rise on vaccine, stimulus news while job cuts buoy Cathay

Hang Seng Index completed a fourth day of gains, with drug maker WuXi Biologics rallying by the most in two years. Alibaba Group powered past the HK$300 mark, adding almost 9 per cent alone this month.

Advertisement
Advertisement
Advertisement
Medicine

WuXi Biologics’ largest investor sells stake for US$893 million windfall

WuXi’s stock has doubled in price since the start of this year, and WuXi Biologics Holdings raised HK$6.1 billion (US$893 million) by selling a 2.43 per cent stake after the market closed on Tuesday. It has now reaped HK$40.7 billion from selling WuXi shares.

videocam
WuXi Biologics’ stock was trading 3.1 per cent lower in Hong Kong on Wednesday afternoon. Photo: Sam Tsang
Hang Seng Index

Xiaomi outpaces Alibaba, Wuxi since being tapped for Hang Seng Index

Xiaomi, Alibaba and Wuxi Biologics join the Hang Seng Index on September 7. Passive fund managers will add them to their holdings. This coming week, Xiaomi reports results on Wednesday. Expect more fireworks, analysts say, after this past week’s rollicking trading.

videocam
Hang Seng Index

Alibaba, Xiaomi, WuXi Biologics to join Hang Seng Index on September 7

23 ETFs with US$20 billion tracking the Hang Seng Index will be able to invest in the tech behemoths with weighted voting rights or secondary listings, strengthening Hong Kong as a tech listing hub.

Health & Fitness

China needs 30 times its outsourcing capacity to meet drugs demand

China will need 30 times its current outsourced manufacturing capacity for biological drugs, according to Chris Chen Zhisheng, CEO of Wuxi Biologics, its largest drugs development and manufacture outsourcing company.

A laboratory in Beijing. China’s drug development industry could require an outsourcing capacity of 3 million litres compared with 100,000 litres currently. Photo: Bloomberg
Health in China

Meet the drug maker that wants to cure China’s tainted vaccine market

Wuxi Biologics is in talks with three separate vaccine developers to manufacture their products in China

videocam
Mainland China’s human vaccine market amounted to 21.6 billion yuan in 2017, or 11.5 per cent of the global total. Photo: AP
IPO

WuXi Biologics surges 37 per cent in Hong Kong debut

Help preserve 120 years of quality journalism.
SUPPORT NOW
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement